BenevolentAI Company

BenevolentAI combines advanced AI and machine learning with cutting edge science to decipher complex disease biology, generate novel insights and discover more effective medicines. Our unique computational R&D platform spans every step of the drug discovery process, powering an in-house pipeline of 25+ drug programmes from early discovery towards clinical phases. With several successful collaborations with leading pharmaceutical organisations, we are also the only AI-drug discovery company with a clinically validated approach, having discovered a leading repurposed drug candidate for COVID-19. BenevolentAI is headquartered in London with a research facility in Cambridge (UK) and a further office in New York, with a team of over 300 world-leading scientists and technologists progressing its mission to reinvent drug discovery and advance life-changing drugs through to the clinic.
Technology: Artificial Intelligence, Big Data, Biotechnology, Machine Learning, Neuroscience
Industry: End-to-end Drug Development
Headquarters: London, England, United Kingdom
Founded Date: 2013-11-13
Employees Number: 51-100
Funding Status: Private Equity
Investors Number: 6
Total Funding: 292000000
Estimated Revenue: $10M to $50M
Last Funding Date: 2019-09-17
Last Funding Type: Private Equity

Visit Website
Register and Claim Ownership